{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:50:14Z","timestamp":1792601414092,"version":"4.5.0"},"reference-count":56,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["2012\/50495-3"],"award-info":[{"award-number":["2012\/50495-3"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.clml.2022.06.012","type":"journal-article","created":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T02:23:56Z","timestamp":1656469436000},"page":"812-824","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Up-front Therapy With CHOP Plus Etoposide in Brazilian nodal PTCL Patients: Increased Toxicity and No Survival Benefit Compared to CHOP Regimen\u2013Results of a Real-Life Study From a Middle-Income Country"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9228-3276","authenticated-orcid":false,"given":"Lu\u00eds Alberto de P\u00e1dua Covas","family":"Lage","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e1udio Vin\u00edcius","family":"Brito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilherme Carneiro","family":"Barreto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6850-8247","authenticated-orcid":false,"given":"Hebert Fabr\u00edcio","family":"Culler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cadiele Oliana","family":"Reichert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D\u00e9bora","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata de Oliveira","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Cl\u00e1udia Nogueira","family":"Zerbini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanderson","family":"Rocha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2022.06.012_bib0001","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.06.012_bib0002","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.bjhh.2015.03.017","article-title":"Primary nodal peripheral T-cell lymphoma: diagnosis and therapeutic considerations","volume":"37","author":"Lage","year":"2015","journal-title":"Rev Bras Hematol Hemoter"},{"key":"10.1016\/j.clml.2022.06.012_bib0003","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International peripheral T-cell and natural-killer\/T-cell lymphoma study: pathology findings and clinical outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.06.012_bib0004","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-3-319-99716-2_1","article-title":"Epidemiology and pathology of T- and NK-cell lymphomas","volume":"176","author":"Siaghani","year":"2019","journal-title":"Cancer Treat Res"},{"key":"10.1016\/j.clml.2022.06.012_bib0005","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1046\/j.1365-2559.2000.00772.x","article-title":"Variation in the histological pattern of nodal involvement by gamma\/delta T-cell lymphoma","volume":"36","author":"Charton-Bain","year":"2000","journal-title":"Histopathology"},{"key":"10.1016\/j.clml.2022.06.012_bib0006","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1093\/annonc\/mdf293","article-title":"Gamma delta T-cell neoplasms: a clinopathological study of 11 cases","volume":"13","author":"Saito","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2022.06.012_bib0007","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1097\/00000478-199706000-00015","article-title":"A nodal gamma\/delta T-cell lymphoma with an association of Epstein-Barr virus","volume":"21","author":"Kagami","year":"1997","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.clml.2022.06.012_bib0008","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1111\/bjh.13202","article-title":"Factors predicting survival in peripheral T-cell lymphoma in the USA: a population-based analysis of 8802 patients in the modern era","volume":"168","author":"Petrich","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2022.06.012_bib0009","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/PAI.0000000000000798","article-title":"Genetic subtypes of systemic anaplastic large cell lymphoma show distinct differences in PD-L1 expression and regulatory and cytotoxic T-cells in the tumor microenvironment","volume":"28","author":"Ferreira","year":"2020","journal-title":"Appl Immunohist Mol Morphol"},{"key":"10.1016\/j.clml.2022.06.012_bib0010","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1007\/s00277-019-03731-w","article-title":"Absolute monocyte count is a predictor of overall survival and progression-free survival in nodal peripheral T-cell lymphoma","volume":"98","author":"Lage","year":"2019","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2022.06.012_bib0011","doi-asserted-by":"crossref","first-page":"5136","DOI":"10.18632\/oncotarget.27098","article-title":"Proliferative, pro-inflammatory, and angiogenesis regulator gene expression profile defines prognosis in different histopathological subtypes of nodal peripheral T-cell lymphoma","volume":"10","author":"Lage","year":"2019","journal-title":"Oncotarget"},{"key":"10.1016\/j.clml.2022.06.012_bib0012","doi-asserted-by":"crossref","first-page":"106794","DOI":"10.1016\/j.leukres.2022.106794","article-title":"Diagnostic and prognostic implications of tumor expression of the GATA-3 gene in nodal peripheral T-cell lymphoma (nPTCL): retrospective data from a Latin American cohort","volume":"114","author":"Lage","year":"2022","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2022.06.012_bib0013","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1365-2141.2011.08651.x","article-title":"Guidelines for the management of mature T-cell and NK-cell neoplasms (excluding cutaneous T-cell lymphomas)","volume":"153","author":"Dearden","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2022.06.012_bib0014","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1002\/ajh.24791","article-title":"The aggressive peripheral T-cell lymphomas: 2017","volume":"92","author":"Armitage","year":"2017","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2022.06.012_bib0015","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/s41568-020-0247-0","article-title":"Peripheral T-cell lymphomas: from the bench to the clinic","volume":"20","author":"Fiore","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.clml.2022.06.012_bib0016","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1002\/hon.2687","article-title":"Event free survival at 24 months is a strong surrogate prognostic endpoint of peripheral T-cell lymphoma","volume":"37","author":"Wudhikarn","year":"2019","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.clml.2022.06.012_bib0017","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jgo.2019.03.016","article-title":"Characteristics, treatment patterns, prognostic determinants and outcome of peripheral T-cell lymphoma and natural-killer\/T cell non-Hodgkin lymphoma in older patients: the result of the nationwide multi-institutional registry Thai Lymphoma Study Group","volume":"11","author":"Wudhikarn","year":"2020","journal-title":"J Geriatr Oncol"},{"key":"10.1016\/j.clml.2022.06.012_bib0018","doi-asserted-by":"crossref","first-page":"727","DOI":"10.3109\/10428194.2013.858154","article-title":"The problem with cyclophosphamide, doxorubicin, vincristine and prednisone for the treatment of peripheral T-cell lymphoma","volume":"55","author":"Kansara","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2022.06.012_bib0019","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.2147\/OTT.S189825","article-title":"Comparison of CHOP vs CHOPE for treatment of peripheral T-cell lymphoma: a meta-analysis","volume":"12","author":"Deng","year":"2019","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.clml.2022.06.012_bib0020","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.06.012_bib0021","doi-asserted-by":"crossref","first-page":"5496","DOI":"10.1182\/blood-2008-01-134270","article-title":"ALK-negative anaplastic large cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project","volume":"111","author":"Savage","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.06.012_bib0022","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1182\/blood-2003-07-2490","article-title":"Targeting the multidrug resistance-1 transporter in AML: molecular regulation and therapeutic strategies","volume":"104","author":"Mahadevan","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.06.012_bib0023","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1182\/blood-2018-09-872549","article-title":"Genetic drivers of oncogenic pathway in molecular subgroups of peripheral T-cell lymphoma","volume":"133","author":"Heavican","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.06.012_bib0024","doi-asserted-by":"crossref","DOI":"10.1186\/s40164-021-00200-x","article-title":"Correlation of mutational landscape and survival outcome of peripheral T-cell lymphoma","volume":"10","author":"Ye","year":"2021","journal-title":"Exp Hematol Oncol"},{"key":"10.1016\/j.clml.2022.06.012_bib0025","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1038\/s41375-019-0473-1","article-title":"Molecular heterogeneity in peripheral T-cell lymphoma, not otherwise specified revealed by comprehensive genetic profiling","volume":"33","author":"Watatani","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2022.06.012_bib0026","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/S0002-9440(10)64261-7","article-title":"Different incidence and pattern of p15INK4b and p16INK4a promoter region hypermethylation in Hodgkin's and CD30-positive non-Hodgkin's lymphomas","volume":"161","author":"Garc\u00eda","year":"2002","journal-title":"Am J Pathol"},{"key":"10.1016\/j.clml.2022.06.012_bib0027","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1182\/blood-2007-02-074641","article-title":"Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial","volume":"110","author":"Gallamini","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.06.012_bib0028","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.3109\/10428194.2012.742521","article-title":"A multicenter phase II trial to determine the safety and efficacy of combination therapy with denileukin-diftitox and cyclophosphamide, doxorubicin, vincristine and prednisone in untreated peripheral T-cell lymphoma: the CONCEPT study","volume":"54","author":"Foss","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2022.06.012_bib0029","doi-asserted-by":"crossref","first-page":"768","DOI":"10.3109\/10428194.2013.816700","article-title":"Bevacizumab and cyclophosphamide, doxorubicin, vincristine and prednisone in combination for patients with peripheral T-cell and natural killer cell neoplasms: an Eastern Cooperative Oncology Group Study (E2404)","volume":"55","author":"Ganjoo","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2022.06.012_bib0030","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/cncr.27733","article-title":"Phase 2 trial of combined cisplatin, etopoide, gemcitabine, and methylprednisolone (PEGS) in peripheral T-cell non-Hodgkin lymphoma: Southwest Oncology Group Study S0350","volume":"119","author":"Mahadevan","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2022.06.012_bib0031","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1200\/JCO.2011.38.0402","article-title":"Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study","volume":"30","author":"Pro","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.06.012_bib0032","first-page":"16","article-title":"The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma","author":"Horwitz","year":"2021","journal-title":"Ann Oncol"},{"issue":"Suppl1","key":"10.1016\/j.clml.2022.06.012_bib0033","article-title":"An exploratory analysis of brentuximab-vedotin plus CHP (A+CHP) in the frontline treatment of patients with CD30+ peripheral T-cell lymphoma (ECHELON-2): impact of consolidative stem cell transplant","volume":"134","author":"Savage","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.06.012_bib0034","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1182\/blood-2010-02-270785","article-title":"Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of German High-Grade Non-Hodgkin Lymphoma Study Group","volume":"116","author":"Schmitz","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.06.012_bib0035","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1182\/blood-2014-04-573089","article-title":"Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry","volume":"124","author":"Ellin","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.06.012_bib0036","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s00280-018-3744-z","article-title":"A retrospective study of the CHOP, CHOPE, and CHOPE\/G regimens as the first-line treatment of peripheral T-cell lymphomas","volume":"83","author":"Liu","year":"2019","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.clml.2022.06.012_bib0037","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/hon.2924","article-title":"Comparison of first-line treatments of peripheral T-cell lymphoma according to regimen: a systematic review and meta-analysis","volume":"39","author":"Kim","year":"2021","journal-title":"Hematol Oncol"},{"issue":"Suppl1","key":"10.1016\/j.clml.2022.06.012_bib0038","article-title":"No added benefit of eight versus six cycles of CHOP when combined with rituximab in previously untreated diffuse large B-cell lymphoma patients: results from the international phase III GOYA study","volume":"132","author":"Sehn","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.06.012_bib0039","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1182\/blood-2015-05-644591","article-title":"IDH2 R172 mutations define a unique subgroup of patients with angioimmunoblastic T-cell lymphoma","volume":"126","author":"Wang","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.06.012_bib0040","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1182\/blood-2012-02-408542","article-title":"Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with THF- like features and adverse clinical parameters","volume":"120","author":"Lemonnier","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.06.012_bib0041","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1056\/NEJMc1111708","article-title":"TET2 and DNMT3A mutations in human T-cell lymphoma","volume":"366","author":"Couronn\u00e9","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2022.06.012_bib0042","doi-asserted-by":"crossref","first-page":"602","DOI":"10.52586\/4970","article-title":"Methylation alterations and advance of treatment in lymphoma","volume":"26","author":"Liu","year":"2021","journal-title":"Front Biosci"},{"key":"10.1016\/j.clml.2022.06.012_bib0043","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1182\/blood.2020009004","article-title":"Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study","volume":"137","author":"Falchi","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.06.012_bib0044","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1200\/JCO.2008.17.4870","article-title":"Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter trial","volume":"27","author":"Reimer","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.06.012_bib0045","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1200\/JCO.2011.40.2719","article-title":"Up-front autologous stem cell transplantation in peripheral T-cell lymphoma: NLG-T-01","volume":"30","author":"d'Amore","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.06.012_bib0046","article-title":"Chemotherapy plus radiotherapy versus chemotherapy alone for patients with peripheral T-cell lymphoma, not otherwise specified","volume":"11","author":"Chen","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.clml.2022.06.012_bib0047","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1182\/blood.2020010387","article-title":"Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: final report from the international T-cell Project","volume":"138","author":"Advani","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.06.012_bib0048","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1182\/blood-2018-04-840538","article-title":"Treatment with 5-azacytidine induces a sustained response in patients with angioimmunoblastic T-cell lymphoma","volume":"132","author":"Lemonnier","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.06.012_bib0049","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1200\/JCO.2014.59.2782","article-title":"Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: results of the pivotal phase II BELIEF (CLN-19) study","volume":"33","author":"O'Connor","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.06.012_bib0050","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s11899-018-0432-3","article-title":"The future of combination therapies for peripheral T cell lymphomas (PTCL)","volume":"13","author":"Ma","year":"2018","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.clml.2022.06.012_bib0051","first-page":"2697","article-title":"ALK+ lymphoma: clinic-pathological findings and outcomes","volume":"93","author":"Fallini","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.06.012_bib0052","first-page":"2993","article-title":"Prognostic significance of CD56 expression for ALK-positive and ALK-negative anaplastic large-cell lymphoma of T\/null cell phenotype","volume":"96","author":"Suzuki","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.06.012_bib0053","doi-asserted-by":"crossref","first-page":"e562","DOI":"10.3324\/haematol.2018.213512","article-title":"ALK-positive anaplastic large-cell lymphoma in adults: an individual patient data pooled analysis of 263 patients","volume":"104","author":"Sibon","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2022.06.012_bib0054","doi-asserted-by":"crossref","first-page":"3939","DOI":"10.1200\/JCO.2012.42.2345","article-title":"Long-term outcome of adults with anaplastic large-cell lymphoma treated within the Gruope d\u00b4Etude des Lymphomes de l\u00b4adulte trials","volume":"30","author":"Sibon","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.06.012_bib0055","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1182\/blood-2010-08-303305","article-title":"Discovery of recurrent t(6;7)(p25.3;q32.3) translocation in ALK-negative anaplastic large-cell lymphomas by massively parallel genomic sequencing","volume":"117","author":"Feldman","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.06.012_bib0056","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1182\/blood-2014-04-571091","article-title":"ALK-negative anaplastic large-cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes","volume":"124","author":"Castellar","year":"2014","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265022002166?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265022002166?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:41:09Z","timestamp":1761871269000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265022002166"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":56,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S2152265022002166"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2022.06.012","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Up-front Therapy With CHOP Plus Etoposide in Brazilian nodal PTCL Patients: Increased Toxicity and No Survival Benefit Compared to CHOP Regimen\u2013Results of a Real-Life Study From a Middle-Income Country","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2022.06.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}